MedTrace Logo

Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials

NCT01799356 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1303

Last updated 2013-08-28

No results posted yet for this study

Summary

We aimed to compare efficacy and safety of combination therapy with oral ofloxacin, 400 mg twice daily, plus oral metronidazole, 500 mg twice daily, for 14 days, with moxifloxacin monotherapy, 400 mg once daily, for 14 days

Conditions

  • Pelvic Inflammatory Disease

Interventions

DRUG

Moxifloxacin

daily 400 mg moksifloksasin

DRUG

Ofloxacin

daily 800 mg oflaksasin plus 1000 mg metronidazol treatment

DRUG

Metronidazole

daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID

Sponsors & Collaborators

  • Istanbul Bakirkoy Maternity and Children Diseases Hospital

    lead OTHER_GOV

Principal Investigators

  • Kemal Gungorduk, md · T.C.S.B. Kanıni Sultan Suleyman Training Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01799356 on ClinicalTrials.gov